This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harker, W. G. Articles by Holguin, M. H. Search for Related Content PubMed PubMed Citation Articles by Harker, W. G. Articles by Holguin, M. H.

Alterations in the Topoisomerase II Gene, Messenger RNA, and Subcellular Protein Distribution as well as Reduced Expression of the DNA Topoisomerase IIß Enzyme in a Mitoxantrone-resistant HL-60 Human Leukemia Cell Line¹

Medicine Service, Veterans Affairs Medical Center and Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah 84148 [W. G. H., D. L. S., R. L. P., M. H. H.] and Departments of Medicine and Biochemistry, James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky 40292 [P. W. F., D. M. S.]

A human HL-60 leukemia cell line selected for resistance to mitoxantrone, HL-60/MX2, displays cross-resistance only to agents whose cytotoxicities result from interaction with the nuclear enzyme DNA topoisomerase II (topo II). The topo II catalytic activity is reduced 2-fold in the drug-resistant cell line in association with the absence of the M_r 180,000 isoform of topo II and the finding of a novel M_r 160,000 topo II -related immunoreactive protein in these cells by immunoblot. The topo II (M_r 170,000) protein levels in nuclear extracts from the HL-60/MX2 cells were noted on average to be 40% lower than in comparable HL-60 nuclei. Studies of the subcellular localization of topo II by immunohistochemical and fractional extraction techniques demonstrated that the M_r 160,000 topo II-related protein is primarily localized in the cytoplasm. Levels of the 6.3-kilobase topo II mRNA were noted to be reduced 2-fold in the HL-60/MX2 cells in association with the finding of a novel 4.8-kilobase topo II-related mRNA transcript that was present in HL-60/MX2 but not HL-60 cells. The absence of topo IIß protein in nuclear and whole cell extracts from the HL-60/MX2 cells was associated with the virtual absence of detectable topo IIß mRNA in those cells by Northern blot analysis. Using a reverse transcription-PCR assay we were able to demonstrate the presence of very low levels of topo IIß mRNA in HL-60/MX2 cells, representing <1% of that found in the HL-60 cells. In contrast, the nuclear catalytic activity and cellular mRNA levels of the related nuclear enzyme DNA topoisomerase I were nearly identical in the two cell types. Southern blot analysis of DNA extracted from the drug-sensitive and drug-resistant cells revealed a structural alteration in one topo II allele in the HL-60/MX2 cells, but there was no evidence of rearrangement or hypermethylation of the topo IIß locus. These results indicate that the reduced levels of topo II and ß isoenzymes observed in mitoxantrone-resistant HL-60/MX2 cells are related to changes in the levels of their respective mRNA transcripts. The identification of structural changes in one topo II allele in the HL-60/MX2 cell line suggests that the altered allele may serve as the source of the unique 4.8-kilobase topo II-related mRNA transcript and the M_r 160,000 protein discovered in those cells.

¹ Supported in part by the Department of Veterans Affairs Medical Research (W. G. H., D. L. S., R. L. P., M. H. H.), by NIH Grants R29-33044 (M. H. H.) and CA59747 (D. M. S.), and by National Cancer Institute CCSG Grant 5P30-CA42014-08 (W. G. H., D. L. S., R. L. P., M. H. H.).

² To whom requests for reprints should be addressed, at Medical Service 111C, Veterans Affairs Medical Center, 500 Foothill Drive, Salt Lake City, UT 84148.

Received 11/15/94. Accepted 2/15/95.

This article has been cited by other articles:

				J. P. Wyles, Z. Wu, S. E.L. Mirski, and S. P.C. Cole Nuclear interactions of topoisomerase II {alpha} and {beta} with phospholipid scramblase 1 Nucleic Acids Res., June 12, 2007; (2007) gkm434v1. [Abstract] [Full Text] [PDF]

				L. P. Swift, A. Rephaeli, A. Nudelman, D. R. Phillips, and S. M. Cutts Doxorubicin-DNA Adducts Induce a Non-Topoisomerase II-Mediated Form of Cell Death. Cancer Res., May 1, 2006; 66(9): 4863 - 4871. [Abstract] [Full Text] [PDF]

				C. S. Morrow, C. Peklak-Scott, B. Bishwokarma, T. E. Kute, P. K. Smitherman, and A. J. Townsend Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux Mol. Pharmacol., April 1, 2006; 69(4): 1499 - 1505. [Abstract] [Full Text] [PDF]

				J. Yun, A. Tomida, T. Andoh, and T. Tsuruo Interaction between Glucose-regulated Destruction Domain of DNA Topoisomerase II{alpha} and MPN Domain of Jab1/CSN5 J. Biol. Chem., July 23, 2004; 279(30): 31296 - 31303. [Abstract] [Full Text] [PDF]

				O. Stuve, M. Kita, D. Pelletier, R. J Fox, J. Stone, D. E Goodkin, and S. S Zamvil Mitoxantrone as a potential therapy for primary progressive multiple sclerosis Multiple Sclerosis, May 1, 2004; 10(3_suppl): S58 - S61. [Abstract] [PDF]

				N. Zhou, H. Xiao, T.-K. Li, A. Nur-E-Kamal, and L. F. Liu DNA Damage-mediated Apoptosis Induced by Selenium Compounds J. Biol. Chem., August 8, 2003; 278(32): 29532 - 29537. [Abstract] [Full Text] [PDF]

				H. Xiao, Y. Mao, S. D. Desai, N. Zhou, C.-Y. Ting, J. Hwang, and L. F. Liu The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway PNAS, March 18, 2003; 100(6): 3239 - 3244. [Abstract] [Full Text] [PDF]

				A. Buschini, P. Poli, and C. Rossi Saccharomyces cerevisiae as an eukaryotic cell model to assess cytotoxicity and genotoxicity of three anticancer anthraquinones Mutagenesis, January 1, 2003; 18(1): 25 - 36. [Abstract] [Full Text] [PDF]

				A. P. Null, J. Hudson, and G. J. Gorbsky Both {alpha} and {beta} Isoforms of Mammalian DNA Topoisomerase II Associate with Chromosomes in Mitosis Cell Growth Differ., July 1, 2002; 13(7): 325 - 333. [Abstract] [Full Text]

				S. K. Diah, P. K. Smitherman, J. Aldridge, E. L. Volk, E. Schneider, A. J. Townsend, and C. S. Morrow Resistance to Mitoxantrone in Multidrug-resistant MCF7 Breast Cancer Cells: Evaluation of Mitoxantrone Transport and the Role of Multidrug Resistance Protein Family Proteins Cancer Res., July 1, 2001; 61(14): 5461 - 5467. [Abstract] [Full Text] [PDF]

				A. SALEEM, T. K. EDWARDS, Z. RASHEED, and E. H. RUBIN Mechanisms of Resistance to Camptothecins Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 46 - 55. [Abstract] [Full Text] [PDF]

				S. Patel, B. A. Keller, and L. M. Fisher Mutations at Arg486 and Glu571 in Human Topoisomerase IIalpha Confer Resistance to Amsacrine: Relevance for Antitumor Drug Resistance in Human Cells Mol. Pharmacol., April 1, 2000; 57(4): 784 - 791. [Abstract] [Full Text]

				F. Errington, E. Willmore, M. J. Tilby, L. Li, G. Li, W. Li, B. C. Baguley, and C. A. Austin Murine Transgenic Cells Lacking DNA Topoisomerase IIbeta Are Resistant to Acridines and Mitoxantrone: Analysis of Cytotoxicity and Cleavable Complex Formation Mol. Pharmacol., December 1, 1999; 56(6): 1309 - 1316. [Abstract] [Full Text]

				T.-K. Li, A. Y. Chen, C. Yu, Y. Mao, H. Wang, and L. F. Liu Activation of topoisomerase II-mediated excision of chromosomal DNA loops during oxidative stress Genes & Dev., June 15, 1999; 13(12): 1553 - 1560. [Abstract] [Full Text]

				L. A. Hazlehurst, N. E. Foley, M. C. Gleason-Guzman, M. P. Hacker, A. E. Cress, L. W. Greenberger, M. C. De Jong, and W. S. Dalton Multiple Mechanisms Confer Drug Resistance to Mitoxantrone in the Human 8226 Myeloma Cell Line Cancer Res., March 1, 1999; 59(5): 1021 - 1028. [Abstract] [Full Text] [PDF]

				S.-P. Sim and L. F. Liu Nucleolytic Cleavage of the Mixed Lineage Leukemia Breakpoint Cluster Region during Apoptosis J. Biol. Chem., August 17, 2001; 276(34): 31590 - 31595. [Abstract] [Full Text] [PDF]